1.
Cancer Research on Prevention and Treatment
; (12): 159-162, 2022.
Artículo
en Chino
| WPRIM (Pacífico Occidental)
| ID: wpr-986494
RESUMEN
Although the first-line treatment regimens represented by R-CHOP have shown good efficacy in B-cell lymphoma, there are still some patients with recurrence and progression. With the advent of the era of tumor immunotherapy, the immunotherapy of B-cell lymphoma has been rapidly developed, including immune checkpoint inhibitors, CAR-cell, tumor microenvironment regulation, etc. This article reviews the current status of immunotherapy of B-cell lymphoma.